642 related articles for article (PubMed ID: 17553486)
1. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
3. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
4. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
5. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
[TBL] [Abstract][Full Text] [Related]
6. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Araya KA; David Pessoa Mahana C; González LG
Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
[TBL] [Abstract][Full Text] [Related]
7. Diuretic effects of cannabinoids.
Paronis CA; Thakur GA; Bajaj S; Nikas SP; Vemuri VK; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Jan; 344(1):8-14. PubMed ID: 23019138
[TBL] [Abstract][Full Text] [Related]
8. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
9. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.
Mendiguren A; Pineda J
Eur J Pharmacol; 2006 Mar; 534(1-3):83-8. PubMed ID: 16483566
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.
Fattore L; Spano S; Cossu G; Deiana S; Fadda P; Fratta W
Neuropharmacology; 2005 Jun; 48(8):1097-104. PubMed ID: 15910886
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
14. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
15. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
17. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity.
Cano C; Goya P; Paez JA; Girón R; Sánchez E; Martín MI
Bioorg Med Chem; 2007 Dec; 15(23):7480-93. PubMed ID: 17870539
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
